William Thies, chief medical & technology officer at the Alzheimer’s Association told CBS News that the findings are still early science, and it could take up to five years to really learn what the study’s implications are. ‘If the speculation of these investigators is correct and you can find a way to interrupt the movement of tau from one neuron to another, that could be a useful therapeutic pathway,’ Thies told CBS News. ‘But there are several steps that have to arrive before you’re actually likely to get to a good product that could be used to treat human disease.’ Around 5.4 million Americans live with Alzheimer’s disease.Other differences were less stark. Generally the lower the socioeconomic position of a patient's region, the more likely they were to receive a high-risk medication. Residents of the poorest areas experienced a 2.7 %age point higher risk than the residents of the richest areas. Complex reasons Trivedi and Qato said the real reason for the gender difference could be straightforward. Some of the risky medications treat ailments particular to ladies or that are more common in women. People living in poor areas, meanwhile, generally have less usage of high quality healthcare, Qato stated, although the bond between poverty and high-risk prescriptions needs further study. The higher threat of receiving potentially harmful prescriptions in poor areas does not describe the geographic variations, Qato said.